NEW YORK, NY / ACCESSWIRE / September 8, 2017 / The markets took a hit on Thursday as banking stocks slid on falling rates and after Walt Disney Co. lowered its 2018 earnings guidance. The Dow Jones Industrial Average declined 0.10 percent to close at 21,784.78, while the S&P 500 Index fell 0.02 percent to close at 2,465.10. Bank of America, Citigroup and Goldman Sachs all declined more than 1 percent as the yield on the benchmark 10-year Treasury note fell 4.7 basis points to settle at 2.061%, which was the lowest since November 8th.

"We're walking away from the prospect of a December rate hike," said Wunderlich Securities chief market strategist Art Hogan. "There certainly is a correlation between banks moving lower and Treasurys moving higher. ... You're seeing an equal but opposite reaction."

RDI Initiates Coverage on:

AVEO Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=AVEO

Celldex Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=CLDX

AVEO Pharmaceuticals Inc.'s stock jumped 16.67% Thursday, to close the day at $3.99. The stock recorded a trading volume of 21,581,251 shares, which was above its three months average volume of 7,893,260 shares. In the last year, AVEO Pharmaceuticals Inc.'s shares have traded in a range of 0.50 - 4.24. The share price has gained 699.60% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $3.00 is greater than its 200-day moving average of $1.51. Shares of AVEO Pharmaceuticals have gained approximately 638.89 percent year-to-date.

Access RDI's AVEO Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AVEO

On Thursday, shares of Celldex Therapeutics Inc. recorded a trading volume of 2,722,559 shares, which was above the three months average volume of 1,432,870 shares. The stock ended the day 9.96% higher at 2.76. The share price has gained 25.45% from its 52 week low with a 52 week trading range of 2.20 - 5.02.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $2.43 is below its 200-day moving average of $2.88. Shares of Celldex Therapeutics have fallen approximately 22.03 percent year-to-date.

Access RDI's Celldex Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLDX

Our Actionable Research on AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com